Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ: BOLT · Real-Time Price · USD
0.3700
+0.0120 (3.35%)
At close: May 12, 2025, 4:00 PM
0.3610
-0.0090 (-2.43%)
After-hours: May 12, 2025, 7:38 PM EDT
Bolt Biotherapeutics Employees
Bolt Biotherapeutics had 52 employees as of December 31, 2024. The number of employees decreased by 48 or -48.00% compared to the previous year.
Employees
52
Change (1Y)
-48
Growth (1Y)
-48.00%
Revenue / Employee
$147,885
Profits / Employee
-$1,213,808
Market Cap
14.19M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 52 | -48 | -48.00% |
Dec 31, 2023 | 100 | 6 | 6.38% |
Dec 31, 2022 | 94 | 3 | 3.30% |
Dec 31, 2021 | 91 | 26 | 40.00% |
Dec 31, 2020 | 65 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
BOLT News
- 8 hours ago - Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 days ago - Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates - GlobeNewsWire
- 12 days ago - Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025 - GlobeNewsWire
- 17 days ago - Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 - GlobeNewsWire
- 6 weeks ago - Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 - GlobeNewsWire
- 7 weeks ago - Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Bolt Biotherapeutics to Participate in Upcoming March Conferences - GlobeNewsWire
- 3 months ago - Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc. - GlobeNewsWire